BACKGROUND:Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. METHODS:Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients receivedSMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 RESULTS: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p < 0.0001) and the oxazepam group (p < 0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. CONCLUSION:SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.
RCT Entities:
BACKGROUND:Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. METHODS:Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 RESULTS: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p < 0.0001) and the oxazepam group (p < 0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. CONCLUSION:SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.
Authors: Beitske E Smink; Berendina J A Hofman; Albert Dijkhuizen; Klaas J Lusthof; Johan J de Gier; Antoine C G Egberts; Donald R A Uges Journal: Br J Clin Pharmacol Date: 2008-06-28 Impact factor: 4.335
Authors: S Jesse; G Bråthen; M Ferrara; M Keindl; E Ben-Menachem; R Tanasescu; E Brodtkorb; M Hillbom; M A Leone; A C Ludolph Journal: Acta Neurol Scand Date: 2016-09-01 Impact factor: 3.209
Authors: Julien Guiraud; Giovanni Addolorato; Mariangela Antonelli; Henri-Jean Aubin; Andrea de Bejczy; Amine Benyamina; Roberto Cacciaglia; Fabio Caputo; Maurice Dematteis; Anna Ferrulli; Anna E Goudriaan; Antoni Gual; Otto-Michael Lesch; Icro Maremmani; Antonio Mirijello; David J Nutt; François Paille; Pascal Perney; Roch Poulnais; Quentin Raffaillac; Jürgen Rehm; Benjamin Rolland; Claudia Rotondo; Bruno Scherrer; Nicolas Simon; Katrin Skala; Bo Söderpalm; Lorenzo Somaini; Wolfgang H Sommer; Rainer Spanagel; Gabriele A Vassallo; Henriette Walter; Wim van den Brink Journal: J Psychopharmacol Date: 2022-07-07 Impact factor: 4.562
Authors: Fabio Caputo; Teo Vignoli; Claudia Tarli; Marco Domenicali; Giorgio Zoli; Mauro Bernardi; Giovanni Addolorato Journal: Int J Environ Res Public Health Date: 2016-03-05 Impact factor: 3.390